Neurizon Clears Ethics Hurdle to Trial Easier-to-Swallow ALS Drug Form
Neurizon clears ethics hurdle for NUZ-001 oral liquid study
The Bellberry Human Research Ethics Committee (HREC) has approved Neurizon Therapeutics Limited’s (ASX: NUZ & NUZOA; OTCQB: NUZTF) Phase 1 formulation study, advancing development of its NUZ-001 oral liquid formulation for amyotrophic lateral sclerosis (ALS), the most common form of motor neurone disease.
The approval represents a meaningful procedural milestone, clearing the path for clinical study initiation and bringing the formulation a step closer to broader patient accessibility.
Neurizon first announced development of the oral liquid formulation on 26 June 2025 as part of its broader ALS development strategy. This HREC approval now advances that work into an active clinical study phase.
When big ASX news breaks, our subscribers know first
Why an oral liquid formulation matters for ALS patients
The swallowing challenge in ALS progression
ALS is a progressive neurodegenerative disease that impairs motor function across the body, including the muscles that control speech and swallowing. The clinical term for swallowing difficulty is dysphagia, and it becomes increasingly prevalent as the disease advances.
For patients at later stages of ALS, swallowing a conventional tablet may no longer be feasible. An oral liquid formulation addresses this directly, offering a practical clinical necessity rather than a convenience. The ability to continue treatment across different stages of disease progression supports continuity of care, and eases the administrative burden on caregivers and clinical teams as much as it does on patients.
What the Phase 1 study involves
The study has been designed with the following parameters:
- 32 healthy volunteers enrolled in Australia
- Randomised, four-arm Phase 1 clinical trial
- Evaluates NUZ-001 oral liquid and tablet formulations under fed and fasted conditions
- Generates pharmacokinetic, safety and tolerability data, alongside exploratory biomarker and palatability data
The data produced will support formulation development and the broader clinical and regulatory development program for NUZ-001. It is important to note this is a formulation study conducted in healthy volunteers, not an efficacy trial in ALS patients.
Milestones, timelines and the broader NUZ-001 program
Study timeline
The forward-looking timeline provides two near-term catalysts investors can monitor:
- Study initiation: Targeted Q3 CY2026 (subject to completion of remaining operational and site initiation activities)
- Study completion: Anticipated Q4 CY2026
Fitting into the bigger picture
This formulation study runs alongside, not instead of, Neurizon’s participation in the Phase 2/3 HEALEY ALS Platform Trial in the United States. The dual-track approach reflects a patient-centred development strategy: building efficacy evidence through a major US-based clinical platform while simultaneously expanding the practical utility and accessibility of NUZ-001 across disease stages.
Sergio Duchini, Interim Executive Chairman, Neurizon Therapeutics
“The oral liquid formulation was developed in direct response to the practical challenges faced by people living with ALS, particularly as swallowing difficulties become more prominent during disease progression. In addition to supporting flexibility and continuity of treatment, the formulation is intended to improve the overall practicality of administration for patients, caregivers and clinical teams.”
The next major ASX story will hit our subscribers first
Investment significance: what HREC approval signals
Ethics committee approval is a gate-keeping step in the clinical development process. Without it, no clinical study can commence. Securing Bellberry HREC approval therefore clears the final procedural barrier before study initiation, which is now targeted for Q3 CY2026.
With study completion anticipated in Q4 CY2026, a data readout is a near-term catalyst on a relatively defined timeline. Importantly, the pharmacokinetic, safety, and tolerability data generated will carry downstream value, supporting clinical, regulatory, and commercial development activities for NUZ-001 beyond this single study.
The table below summarises the key milestones at a glance:
| Milestone | Detail | Timeline | Significance |
|---|---|---|---|
| HREC approval | Bellberry ethics committee | May 2026 | Clears path to study initiation |
| Study initiation | 32 healthy volunteers, Australia | Q3 CY2026 | Near-term catalyst |
| Study completion | PK, safety, tolerability and biomarker data | Q4 CY2026 | Supports regulatory and commercial pathway |
| HEALEY Trial | Phase 2/3, United States | Ongoing | Parallel efficacy program |
Investors should note that NUZ-001 remains an investigational product and is not approved for commercial use in any jurisdiction.
Don’t Miss the Next Healthcare Breakthrough
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ investors who stay ahead of the market the moment announcements drop. Click the “Free Alerts” button to start receiving real-time coverage across ASX healthcare and beyond.